Celldex/$CLDX
1D1W1MYTD1Y5YMAX
Capital at risk
About Celldex
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
- Ticker
- $CLDX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 198
- Headquarters
- Hampton, United States
- Website
- www.celldex.com
Celldex Metrics
BasicAdvanced
$3.1B
-
-$4.33
0.84
-
Price and volume
Market cap
$3.1B
Beta
0.84
52-week high
$45.14
52-week low
$22.10
Average daily volume
779K
Financial strength
Current ratio
11.821
Quick ratio
11.705
Long term debt to equity
0.005
Total debt to equity
0.007
Profitability
EBITDA (TTM)
-322.432
Gross margin (TTM)
-176,360.13%
Net profit margin (TTM)
-190,220.89%
Operating margin (TTM)
-206,220.25%
Management effectiveness
Return on assets (TTM)
-27.62%
Return on equity (TTM)
-43.88%
Valuation
Price to revenue (TTM)
17,111.501
Price to book
4.28
Price to tangible book (TTM)
4.45
Price to free cash flow (TTM)
-11.165
Free cash flow yield (TTM)
-8.96%
Free cash flow per share (TTM)
-3.491
Growth
Revenue change (TTM)
-97.27%
Earnings per share change (TTM)
44.10%
3-year revenue growth (CAGR)
-63.52%
10-year revenue growth (CAGR)
-29.89%
3-year earnings per share growth (CAGR)
21.67%
10-year earnings per share growth (CAGR)
-14.16%
What the Analysts think about Celldex
Analyst ratings (Buy, Hold, Sell) for Celldex stock.
Analyst projections of the future price of Celldex stock.
Bulls say / Bears say
Celldex presented positive Phase 2 data for barzolvolimab in chronic spontaneous urticaria (CSU), cold urticaria (ColdU) and symptomatic dermographism (SD), meeting primary efficacy endpoints and reinforcing its first‐in‐class profile (Reuters)
The company ended Q2 2026 with $717.6 million in cash, cash equivalents and marketable securities, providing a runway through 2028 and reducing near‐term funding risk (Reuters)
Enrollment in the global Phase 3 CSU studies (EMBARQ-CSU1 and ‑CSU2) was completed six months ahead of guidance with 1,939 patients enrolled across 43 countries, demonstrating strong demand and efficient execution (Reuters)
Discontinuation of barzolvolimab development in prurigo nodularis after the candidate failed to meet primary and key secondary endpoints in a mid‐stage study, sending shares down over 7% in extended trading (Reuters)
Second quarter FY26 net loss widened to $73.5 million, or ($0.94) per share, up from $56.6 million in Q2 2025, driven by higher R&D and G&A expenses for barzolvolimab trials (Reuters)
Reliance on a single lead asset exposes the equity to binary risk, as topline data from the pivotal Phase 3 CSU trials expected in September/October 2026 represent a critical milestone whose failure could trigger a steep re‐rating (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 23 Aug 2026.
Celldex Financial Performance
Revenues and expenses
Celldex Earnings Performance
Company profitability
Upcoming events
No upcoming events
Celldex News
AllArticlesVideos
Funds containing Celldex
AllEURGBPUSD
Fund name | Fund size | $CLDX weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.10% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.08% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.08% |
iShares MSCI World Small Cap$WSML | $9B | 0.03% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.